The latter is an FDA-approved treatment for primary liver cancer (HCC) which has been shown in clinical trials to increase the survival rate of low-risk patients.
後者是FDA批准的原發性肝癌（特指HCC）治療，已在臨床試驗中顯示，以提高低危患者的生存率。